Mural Oncology (MURA) Competitors $3.35 -0.02 (-0.59%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MURA vs. ZNTL, AMRN, SLDB, GNFT, LXEO, MOLN, CRBP, SOPH, TCRX, and TRVIShould you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Zentalis Pharmaceuticals (ZNTL), Amarin (AMRN), Solid Biosciences (SLDB), Genfit (GNFT), Lexeo Therapeutics (LXEO), Molecular Partners (MOLN), Corbus Pharmaceuticals (CRBP), SOPHiA GENETICS (SOPH), TScan Therapeutics (TCRX), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry. Mural Oncology vs. Zentalis Pharmaceuticals Amarin Solid Biosciences Genfit Lexeo Therapeutics Molecular Partners Corbus Pharmaceuticals SOPHiA GENETICS TScan Therapeutics Trevi Therapeutics Mural Oncology (NASDAQ:MURA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk. Does the MarketBeat Community favor MURA or ZNTL? Zentalis Pharmaceuticals received 54 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 100.00% of users gave Mural Oncology an outperform vote while only 63.44% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMural OncologyOutperform Votes5100.00% Underperform VotesNo VotesZentalis PharmaceuticalsOutperform Votes5963.44% Underperform Votes3436.56% Do analysts recommend MURA or ZNTL? Mural Oncology presently has a consensus price target of $16.00, indicating a potential upside of 377.61%. Zentalis Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 209.60%. Given Mural Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Mural Oncology is more favorable than Zentalis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mural Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Does the media favor MURA or ZNTL? In the previous week, Zentalis Pharmaceuticals had 6 more articles in the media than Mural Oncology. MarketBeat recorded 13 mentions for Zentalis Pharmaceuticals and 7 mentions for Mural Oncology. Mural Oncology's average media sentiment score of 1.02 beat Zentalis Pharmaceuticals' score of 0.58 indicating that Mural Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mural Oncology 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, MURA or ZNTL? Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMural OncologyN/AN/A-$207.45M-$9.14-0.37Zentalis PharmaceuticalsN/AN/A-$292.19M-$2.49-1.30 Do insiders and institutionals believe in MURA or ZNTL? 80.2% of Mural Oncology shares are held by institutional investors. 0.1% of Mural Oncology shares are held by company insiders. Comparatively, 3.6% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is MURA or ZNTL more profitable? Zentalis Pharmaceuticals' return on equity of -43.91% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Mural OncologyN/A -70.10% -61.30% Zentalis Pharmaceuticals N/A -43.91%-34.96% SummaryMural Oncology beats Zentalis Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Mural Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MURA vs. The Competition Export to ExcelMetricMural OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.02M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-0.3710.35102.4617.58Price / SalesN/A362.011,234.85158.43Price / CashN/A52.6040.4736.33Price / Book0.3310.377.096.50Net Income-$207.45M$153.60M$119.65M$226.22M7 Day Performance-2.90%3.92%2.06%3.76%1 Month Performance-2.90%-6.78%-2.46%4.63%1 Year PerformanceN/A33.23%33.95%29.20% Mural Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MURAMural Oncology3.2942 of 5 stars$3.35-0.6%$16.00+377.6%N/A$57.02MN/A-0.37119Positive NewsZNTLZentalis Pharmaceuticals2.4127 of 5 stars$3.23+1.6%$10.00+209.6%-69.0%$226.62MN/A0.00160AMRNAmarin0.0968 of 5 stars$0.55+3.8%N/A-29.4%$225.29M$306.91M-6.10360SLDBSolid Biosciences3.3502 of 5 stars$5.41+3.4%$15.14+179.9%+106.5%$216.16M$8.09M-1.81100Analyst RevisionGNFTGenfit1.4465 of 5 stars$4.29+1.2%$13.00+203.0%+32.8%$214.30M$76.06M0.00120News CoverageLXEOLexeo Therapeutics2.1286 of 5 stars$6.47+4.4%$22.71+251.1%-40.6%$213.94M$650,000.00-2.0858MOLNMolecular Partners0.2478 of 5 stars$5.28-2.6%$4.50-14.8%+21.7%$213.00M$7.84M-2.46180Gap UpCRBPCorbus Pharmaceuticals4.8584 of 5 stars$17.47+4.4%$65.86+277.0%+306.3%$212.77M$880,000.00-3.5940SOPHSOPHiA GENETICS1.4077 of 5 stars$3.22+2.9%$6.50+101.9%-12.0%$210.52M$62.37M-2.95520TCRXTScan Therapeutics2.7919 of 5 stars$4.26+8.1%$12.00+181.7%-18.7%$210.28M$21.05M0.00100TRVITrevi Therapeutics3.4443 of 5 stars$2.91+6.6%$7.43+155.3%+155.3%$209.84MN/A0.0020High Trading Volume Related Companies and Tools Related Companies Zentalis Pharmaceuticals Competitors Amarin Competitors Solid Biosciences Competitors Genfit Competitors Lexeo Therapeutics Competitors Molecular Partners Competitors Corbus Pharmaceuticals Competitors SOPHiA GENETICS Competitors TScan Therapeutics Competitors Trevi Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MURA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
